Annette Paschen

10PUBLICATIONS
88CO-AUTHORS
Molecular targetsCancer cell biologyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|May 13, 2026
Targeted degradation of USP7 in solid cancer cells reveals distinct effects of deubiquitinase degraders and inhibitors.

|Apr 16, 2026
Stress-induced proteome remodeling at the Golgi-endosome interface.

|Apr 30, 2024
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial.

Martin Schuler, Kristof Cuppens, Till Plönes

|Aug 14, 2023
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.

Renáta Váraljai, Lisa Zimmer, Yahya Al-Matary

|Jul 31, 2023
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.

Renáta Váraljai, Lisa Zimmer, Yahya Al-Matary

|May 18, 2023
HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance.

Simone Stupia, Christina Heeke, Alicia Brüggemann

Pageof 2

Frequent Collaborators

5 joint publications

Dirk Schadendorf

4 joint publications

Alexander Roesch

4 joint publications

Fang Zhao

3 joint publications

Renáta Váraljai